Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » BioLegend Licenses Single-Cell Analysis Technology from New York Genome Center

BioLegend Licenses Single-Cell Analysis Technology from New York Genome Center

Jan 11, 2018
|
staff reporter

NEW YORK (GenomeWeb) – BioLegend has licensed a multidimensional single-cell analysis technology from the New York Genome Center and is collaborating with the center on further research, the two organizations said today.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Increased Genetic Privacy in Florida

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

Working Out the Effect

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Attention-Grabbing in Two Ways

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

Nature Papers Describe CRISPR Plant Editing Methods, DNA-PAINT Improvements, More

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

What's Popular?

In Business News

  1. Surge in Stocks of SARS-CoV-2 Dx Developers Pushes GenomeWeb Index Up 15 Percent in H1 2020

  2. Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index

  3. Centogene Gets Emergency Use Authorization for PCR-Based Coronavirus Test

  4. FDA Issues Warning Letter to Luminex

  5. Sherlock Biosciences, Binx Health Partner to Develop CRISPR-Based POC COVID-19 Test

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.